Gastrointestinal stromal tumor: genes and variants
Explore variant evidence for Gastrointestinal stromal tumor across 11 analyzed proteins (SDHB, KIT, SDHC, PDGFRA, SDHA and 6 more). Linked ClinVar records include 93 pathogenic or likely pathogenic variants, 3,007 variants of uncertain significance and 413 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Gastrointestinal stromal tumor
SDHB: Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial
It transfers electrons from succinate oxidation through iron-sulfur centers toward ubiquinone in mitochondrial complex II. Heterozygous loss-of-function variants strongly predispose to paraganglioma and pheochromocytoma and can also increase renal-tumor and gastrointestinal-stromal-tumor risk.
53 ClinVar pathogenic / likely pathogenic and 447 uncertain variants in SDHB have source records linked to Gastrointestinal stromal tumor. Association strength is not clinical gene validity.
KIT: Mast/stem cell growth factor receptor Kit
Stem-cell-factor signaling through this pathway supports hematopoietic progenitors, mast cells, melanocytes, and germ cells. Activating variants drive gastrointestinal stromal tumors, systemic mastocytosis, and other malignancies, whereas loss-of-function variants can cause piebaldism.
23 ClinVar pathogenic / likely pathogenic and 1,281 uncertain variants in KIT have source records linked to Gastrointestinal stromal tumor. Association strength is not clinical gene validity.
SDHC: Succinate dehydrogenase cytochrome b560 subunit, mitochondrial
It anchors succinate dehydrogenase to the inner mitochondrial membrane and helps transfer electrons from the catalytic subunits to ubiquinone. Heterozygous loss-of-function variants predispose to paraganglioma, pheochromocytoma, and some gastrointestinal stromal tumors.
16 ClinVar pathogenic / likely pathogenic and 261 uncertain variants in SDHC have source records linked to Gastrointestinal stromal tumor. Association strength is not clinical gene validity.
PDGFRA: Platelet-derived growth factor receptor alpha
PDGF signaling through this pathway promotes proliferation, survival, and migration of mesenchymal progenitors. Activating mutations or fusions drive gastrointestinal stromal tumors and selected hematologic and solid malignancies and can create kinase-inhibitor sensitivity.
1 ClinVar pathogenic / likely pathogenic and 1,427 uncertain variants in PDGFRA have source records linked to Gastrointestinal stromal tumor. Association strength is not clinical gene validity.
SDHA: Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial
It catalyzes oxidation of succinate to fumarate while transferring electrons into respiratory-chain complex II, directly linking the TCA cycle with oxidative phosphorylation. Biallelic deficiency can cause mitochondrial disease, while heterozygous loss-of-function variants predispose to paraganglioma, pheochromocytoma, and selected gastrointestinal stromal tumors.
0 ClinVar pathogenic / likely pathogenic and 4 uncertain variants in SDHA have source records linked to Gastrointestinal stromal tumor. Association strength is not clinical gene validity.
ABL1: Tyrosine-protein kinase ABL1
It coordinates cytoskeletal remodeling, adhesion, DNA-damage responses, and growth signaling through tightly regulated tyrosine phosphorylation. Fusion with BCR removes normal control and creates the constitutively active kinase that drives chronic myeloid leukemia and subsets of acute lymphoblastic leukemia.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ABL1 have source records linked to Gastrointestinal stromal tumor. Association strength is not clinical gene validity.
BCR: Breakpoint cluster region protein
It has serine/threonine kinase and GTPase-regulatory functions involved in cytoskeletal and signaling control. Chromosomal fusion with ABL1 creates the constitutively active BCR::ABL1 kinase that drives chronic myeloid leukemia and subsets of acute leukemia.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in BCR have source records linked to Gastrointestinal stromal tumor. Association strength is not clinical gene validity.
CSF1R: Macrophage colony-stimulating factor 1 receptor
Signals from CSF1 and IL-34 through this pathway are required for development, survival, and function of macrophages and microglia. Pathogenic variants can cause adult-onset leukoencephalopathy with cognitive, psychiatric, and motor deterioration.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CSF1R have source records linked to Gastrointestinal stromal tumor. Association strength is not clinical gene validity.
FLT3: Receptor-type tyrosine-protein kinase FLT3
Its signaling supports survival and expansion of early hematopoietic progenitors. Internal tandem duplications and kinase-domain mutations produce constitutive activity in acute myeloid leukemia and are important prognostic markers and therapeutic targets.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in FLT3 have source records linked to Gastrointestinal stromal tumor. Association strength is not clinical gene validity.
PDGFRB: Platelet-derived growth factor receptor beta
Its signaling supports pericytes, vascular smooth-muscle cells, and other mesenchymal lineages during growth and tissue repair. Oncogenic fusions drive myeloid neoplasms, while germline activating or loss-of-function variants can cause developmental and vascular disorders.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PDGFRB have source records linked to Gastrointestinal stromal tumor. Association strength is not clinical gene validity.
RET: Proto-oncogene tyrosine-protein kinase receptor Ret
Its activation by GDNF-family ligands guides development of the enteric nervous system, kidney, and other tissues. Activating variants cause multiple endocrine neoplasia type 2 and can drive cancer, whereas loss-of-function variants are an important cause of Hirschsprung disease.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in RET have source records linked to Gastrointestinal stromal tumor. Association strength is not clinical gene validity.
Where Gastrointestinal stromal tumor variants cluster
- KIT Cytoplasmic (positions 546–976): 15 of 16 ClinVar pathogenic / likely pathogenic variants, 2.1× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Gastrointestinal stromal tumor
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| SDHB R46L | 46 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB G96S | 96 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB G96D | 96 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB C192R | 192 | 4Fe-4S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB C196Y | 196 | 4Fe-4S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB W200C | 200 | 4Fe-4S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB W200R | 200 | 4Fe-4S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB R217C | 217 | Interaction with SDHAF1 | Pathogenic / likely pathogenic (★★) |
| SDHB R217G | 217 | Interaction with SDHAF1 | Pathogenic / likely pathogenic (★★) |
| SDHB R217L | 217 | Interaction with SDHAF1 | Pathogenic / likely pathogenic (★★) |
| SDHB R230L | 230 | Pathogenic / likely pathogenic (★★) | |
| SDHB R242C | 242 | Pathogenic / likely pathogenic (★★) | |
| SDHB R242S | 242 | Pathogenic / likely pathogenic (★★) | |
| KIT V559A | 559 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SDHB R46G | 46 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB R46Q | 46 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB D74A | 74 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB C98R | 98 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB C98Y | 98 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB D138Y | 138 | Pathogenic / likely pathogenic (★★) | |
| SDHB C189Y | 189 | 4Fe-4S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB C189F | 189 | 4Fe-4S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB C192Y | 192 | 4Fe-4S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB R217S | 217 | Interaction with SDHAF1 | Pathogenic / likely pathogenic (★★) |
| SDHB R230C | 230 | Pathogenic / likely pathogenic (★★) | |
| SDHB R230H | 230 | Pathogenic / likely pathogenic (★★) | |
| SDHB R242H | 242 | Pathogenic / likely pathogenic (★★) | |
| SDHC R72H | 72 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SDHC R72C | 72 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SDHC H127R | 127 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SDHC H127Y | 127 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SDHC H127N | 127 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| KIT V560A | 560 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SDHB M1I | 1 | Pathogenic / likely pathogenic (★★) | |
| SDHB I127S | 127 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB P197R | 197 | 4Fe-4S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB C253Y | 253 | Pathogenic / likely pathogenic (★★) | |
| SDHC M1R | 1 | Pathogenic / likely pathogenic (★★) | |
| SDHC R72L | 72 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SDHC R72G | 72 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SDHB M1L | 1 | Pathogenic / likely pathogenic (★★) | |
| SDHB M1V | 1 | Pathogenic / likely pathogenic (★★) | |
| SDHB A43P | 43 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB C93R | 93 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB G99D | 99 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB H132P | 132 | 2Fe-2S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB V140F | 140 | Pathogenic / likely pathogenic (★★) | |
| SDHB C191Y | 191 | 4Fe-4S ferredoxin-type | Pathogenic / likely pathogenic (★★) |
| SDHB G208R | 208 | Interaction with SDHAF1 | Pathogenic / likely pathogenic (★★) |
| SDHB G208E | 208 | Interaction with SDHAF1 | Pathogenic / likely pathogenic (★★) |
| SDHB Q214R | 214 | Interaction with SDHAF1 | Pathogenic / likely pathogenic (★★) |
| SDHB C243W | 243 | Pathogenic / likely pathogenic (★★) | |
| SDHC M1I | 1 | Pathogenic / likely pathogenic (★★) | |
| SDHC R50C | 50 | Mitochondrial matrix | Pathogenic / likely pathogenic (★★) |
| SDHC G75D | 75 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SDHC Y126C | 126 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| KIT W557R | 557 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| KIT N819K | 819 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| KIT D820Y | 820 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| KIT N822K | 822 | Protein kinase | Pathogenic / likely pathogenic (★★) |
Showing 60 of 93.
Uncertain variants prioritized for review in Gastrointestinal stromal tumor
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| SDHB Q214H | 214 | Interaction with SDHAF1 | Conflicting reports (★) | +7: 5 other pathogenic changes within 3 positions; Q214R at the same position is pathogenic; seen in 6.9e-07 of gnomAD DNA copies; REVEL 0.891 |
| SDHB H132R | 132 | 2Fe-2S ferredoxin-type | Uncertain (★★) | +7: in a 3D region that tolerates change poorly (1R); H132P at the same position is pathogenic; seen in 3.4e-06 of gnomAD DNA copies; REVEL 0.896 |
| SDHB L65F | 65 | 2Fe-2S ferredoxin-type | Uncertain (★★) | +7: 2 other pathogenic changes within 3 positions; L65P at the same position is pathogenic; seen in 3.4e-06 of gnomAD DNA copies; REVEL 0.775 |
| SDHB V140D | 140 | Conflicting reports (★) | +6: 3 other pathogenic changes within 3 positions; V140F at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 | |
| SDHB C192S | 192 | 4Fe-4S ferredoxin-type | Conflicting reports (★) | +6: 6 other pathogenic changes within 3 positions; C192Y at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| SDHB C113G | 113 | 2Fe-2S ferredoxin-type | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; C113S at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.99 |
| SDHB C93F | 93 | 2Fe-2S ferredoxin-type | Conflicting reports (★) | +6: 3 other pathogenic changes within 3 positions; C93R at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| SDHB G96C | 96 | 2Fe-2S ferredoxin-type | Conflicting reports (★) | +6: 6 other pathogenic changes within 3 positions; G96S at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| SDHB C189R | 189 | 4Fe-4S ferredoxin-type | Conflicting reports (★) | +6: 7 other pathogenic changes within 3 positions; C189W at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| SDHB G96V | 96 | 2Fe-2S ferredoxin-type | Conflicting reports (★) | +6: 6 other pathogenic changes within 3 positions; G96S at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| SDHB R217H | 217 | Interaction with SDHAF1 | Conflicting reports (★) | +6: 5 other pathogenic changes within 3 positions; R217S at the same position is pathogenic; REVEL 0.957 |
| SDHB C68R | 68 | 2Fe-2S ferredoxin-type | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; C68Y at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.98 |
| SDHB C186R | 186 | 4Fe-4S ferredoxin-type | Uncertain (★) | +6: 4 other pathogenic changes within 3 positions; C186Y at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| SDHB C186S | 186 | 4Fe-4S ferredoxin-type | Uncertain (★) | +6: 4 other pathogenic changes within 3 positions; C186Y at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| SDHB P197L | 197 | 4Fe-4S ferredoxin-type | Uncertain (★) | +6: 5 other pathogenic changes within 3 positions; P197R at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.98 |
| SDHB G99S | 99 | 2Fe-2S ferredoxin-type | Uncertain (★★) | +6: 5 other pathogenic changes within 3 positions; G99D at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.98 |
| SDHB G96R | 96 | 2Fe-2S ferredoxin-type | Uncertain (★) | +6: 6 other pathogenic changes within 3 positions; G96S at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| SDHB W200G | 200 | 4Fe-4S ferredoxin-type | Uncertain (★) | +6: 3 other pathogenic changes within 3 positions; W200C at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.96 |
| SDHC R50L | 50 | Mitochondrial matrix | Uncertain (★★) | +6: R50C at the same position is pathogenic; REVEL 0.956 |
| SDHB D74N | 74 | 2Fe-2S ferredoxin-type | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; D74G at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.98 |
| SDHC R50H | 50 | Mitochondrial matrix | Uncertain (★★) | +6: R50C at the same position is pathogenic; REVEL 0.945 |
| KIT D816V | 816 | Protein kinase | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; D816Y at the same position is pathogenic; REVEL 0.890 |
| KIT V559F | 559 | Cytoplasmic | Uncertain (★★) | +6: 5 other pathogenic changes within 3 positions; V559D at the same position is pathogenic; REVEL 0.774 |
| SDHB I127L | 127 | 2Fe-2S ferredoxin-type | Uncertain (★★) | +6: in a 3D region that tolerates change poorly (1R); I127S at the same position is pathogenic; seen in 1.4e-06 of gnomAD DNA copies; REVEL 0.724 |
Which prediction tools work for Gastrointestinal stromal tumor
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- REVEL: 100 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 100 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 100 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 97 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 97 out of 100
- AlphaMissense: 97 out of 100
- EVE: 96 out of 100
- CADD: 95 out of 100
- SIFT: 90 out of 100
- PolyPhen-2: 89 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- phyloP: 88 out of 100
- SpliceAI: 51 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 36 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Piebaldism also has ClinVar records linked to KIT variants; they fall mostly in different places as the Gastrointestinal stromal tumor variants (8 pathogenic / likely pathogenic).
- Cutaneous mastocytosis also has ClinVar records linked to KIT variants; they fall partly in the same places as the Gastrointestinal stromal tumor variants (3 pathogenic / likely pathogenic).
Diseases related to Gastrointestinal stromal tumor
- Renal cell carcinoma, also linked to CSF1R, FLT3, KIT, PDGFRA and 2 more
- Colorectal cancer, also linked to ABL1, KIT, PDGFRA, PDGFRB and 1 more
- Acute lymphoid leukemia, also linked to ABL1, BCR, FLT3, KIT and 1 more
- Acute myeloid leukemia, also linked to FLT3, KIT, PDGFRA and PDGFRB
- Hepatocellular carcinoma, also linked to FLT3, KIT, PDGFRB and RET
- Chronic myeloid leukemia, also linked to ABL1, BCR, KIT and PDGFRB
- Pheochromocytoma/paraganglioma syndrome, also linked to SDHA, SDHB and SDHC
- Ovarian cancer, also linked to KIT, PDGFRA and RET
- Non-small cell lung carcinoma, also linked to PDGFRA, PDGFRB and RET
- Inherited phaeochromocytoma and paraganglioma excluding NF1, also linked to SDHA, SDHB and SDHC
- Hereditary pheochromocytoma and paraganglioma, also linked to SDHA, SDHB and SDHC
- Pheochromocytoma, also linked to RET and SDHB
Frequently asked questions
Which genes have records linked to Gastrointestinal stromal tumor?
This view contains 11 analyzed proteins: SDHB, KIT, SDHC, PDGFRA, SDHA and 6 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 93 pathogenic or likely pathogenic variants, 3,007 variants of uncertain significance and 413 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 24 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 3,560 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center